Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial

BACKGROUND: Currently available disease-modifying treatments acting by modifying the immune response are ineffective in progressive multiple sclerosis (MS), which is caused by a widespread axonal degeneration. Mechanisms suspected to be involved in this widespread axonal degeneration are reduced axo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cambron, Melissa, Mostert, Jop, Haentjens, Patrick, D’Hooghe, Marie, Nagels, Guy, Willekens, Barbara, Heersema, Dorothea, Debruyne, Jan, Van Hecke, Wim, Algoed, Luc, De Klippel, Nina, Fosselle, Erwin, Laureys, Guy, Merckx, Henri, Van Wijmeersch, Bart, Vanopdenbosch, Ludo, Verhagen, Wim, Hupperts, Raymond, Hengstman, Gerald, Michiels, Veronique, Van Merhaegen-Wieleman, Annick, De Keyser, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931920/
https://www.ncbi.nlm.nih.gov/pubmed/24460863
http://dx.doi.org/10.1186/1745-6215-15-37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931920/
https://www.ncbi.nlm.nih.gov/pubmed/24460863
http://dx.doi.org/10.1186/1745-6215-15-37

Ejemplares similares